 WATERTOWN, Mass., Nov. 05, 2021 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference call to highlight interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD on Saturday, November 13 at 12:00 P.M. ET11:00 A.M. CST. Dr. Carl Regillo, KOL and Chair of the Companys Scientific Advisory Board, will be participating in the live event. 